| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 05/04/2004 | US6730329 Zinc containing compositions for anti-viral use |
| 05/04/2004 | US6730328 Stable protein and nucleic acid formulations using non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity |
| 05/04/2004 | US6730327 Polymer blends that swell in an acidic environment and deswell in a basic environment |
| 05/04/2004 | US6730325 Multiparticulate modified release composition |
| 05/04/2004 | US6730324 Biofunctional hydroxyapatite coatings and microspheres for in-situ drug encapsulation |
| 05/04/2004 | US6730323 Aqueous solution containing carbomer, propylene glycol, glycerin, dmdm hydantoin, citric acid, chondroitin sulfate, animal protein and triethanolamine |
| 05/04/2004 | US6730322 Delaying release of encapsulated active material; using lipid or other hydrophobic or amphiphilic compound |
| 05/04/2004 | US6730321 Press coated, pulsatile drug delivery system suitable for oral administration |
| 05/04/2004 | US6730320 Doxycycline administered in three dosages forms of different release profiles, with cmax being reached in < twelve hours |
| 05/04/2004 | US6730319 Pharmaceutical compositions having depressed melting points |
| 05/04/2004 | US6730318 Transdermal delivery devices containing polydiorganosiloxane polymers to regulate adhesive properties |
| 05/04/2004 | US6730317 Patch, a kit constituted by a patch and a receptacle and a method |
| 05/04/2004 | US6730315 Medium and matrix for long-term proliferation of cells |
| 05/04/2004 | US6730313 Adheres to injury site; releases bioactive agent that reduces or prevents further damage |
| 05/04/2004 | US6730288 Lower level of occlusive agent; greater drug skin penetration |
| 05/04/2004 | US6730072 Methods and devices for sealing microchip reservoir devices |
| 05/04/2004 | US6730060 Implantable device for administering a treatment solution and operating device for a syringe for filling the device |
| 05/04/2004 | CA2213638C Aerosols containing nanoparticle dispersions |
| 05/04/2004 | CA2201631C Liposome-formulations for treatment of viral diseases |
| 04/30/2004 | WO2004039294A1 Heat generating article |
| 04/30/2004 | CA2435262A1 Heat-generating body |
| 04/30/2004 | CA2418998A1 Applicator and method for applying lanolin to a sore nipple |
| 04/30/2004 | CA2417320A1 Applicator and method for applying lanolin to a sore nipple |
| 04/29/2004 | WO2004036186A2 Microencapsulation and sustained release of biologically active polypeptides |
| 04/29/2004 | WO2004035762A2 Microencapsulation and sustained release of biologically active polypeptides |
| 04/29/2004 | WO2004035754A2 Microencapsulation and sustained release of biologically active polypeptides |
| 04/29/2004 | WO2004035728A1 System for delivery of active substances |
| 04/29/2004 | WO2004035523A1 Cationic cardiolipin analogs and use thereof |
| 04/29/2004 | WO2004035109A2 Apparatus and methods for activating a delivery device |
| 04/29/2004 | WO2004035096A1 Composition exhibiting stabilised oxidation-reduction properties and method for the stabilisation thereof |
| 04/29/2004 | WO2004035093A2 Polymeric materials for site specific delivery to the body |
| 04/29/2004 | WO2004035090A1 Gastric acid secretion inhibiting composition |
| 04/29/2004 | WO2004035077A1 Phosphoprotein preparations for bioactive metal ion delivery and teeth remineralisation |
| 04/29/2004 | WO2004035060A1 Bisphosphonates for the treatment of antheroscleorosis and devices comprising them |
| 04/29/2004 | WO2004035054A1 Transdermal patch for external use comprising fentanyl |
| 04/29/2004 | WO2004035052A1 Stable solid preparations |
| 04/29/2004 | WO2004035046A1 Powder inhalant of sumatriptan and the method of preparation thereof |
| 04/29/2004 | WO2004035044A1 Dry syrup preparation of procaterol comprising ascorbinic acid and citric acid |
| 04/29/2004 | WO2004035032A2 Pharmaceutical formulations of camptothecine derivatives |
| 04/29/2004 | WO2004035029A1 Edible phosphoprotein film |
| 04/29/2004 | WO2004035028A1 Method for producing the microcapsulated form of a live viral vaccine |
| 04/29/2004 | WO2004035027A1 Pharmaceutical formulation of olanzapine |
| 04/29/2004 | WO2004035026A1 Deferacirox dispersible tablets |
| 04/29/2004 | WO2004035025A1 Agent for oral administration, containing a tablet made of konjac flour and which is insoluble or poorly soluble in water or in a gastrointestinal medium |
| 04/29/2004 | WO2004035024A1 Dosage form of sodium ibuprofen |
| 04/29/2004 | WO2004035022A2 Prepolymeric materials for site specific delivery to the body |
| 04/29/2004 | WO2004035021A2 Buccal polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
| 04/29/2004 | WO2004035020A2 Controlled release preparation |
| 04/29/2004 | WO2004035005A2 Three layer tear formulation |
| 04/29/2004 | WO2004035004A2 Effervescent compositions comprising bisphosphonates and methods related thereto |
| 04/29/2004 | WO2004034992A2 Encapsulation and deaggregation of polyene antibiotics using poly(ethylene glycol)-phospholipid micelles |
| 04/29/2004 | WO2004034982A2 Treatment termination in a medical device |
| 04/29/2004 | WO2004034981A2 Compositions and methods for inhibiting group b streptococcus-induced pulmonary hypertension in neonates |
| 04/29/2004 | WO2004034975A2 Sustained release profile modification |
| 04/29/2004 | WO2004034963A2 Methods and compositions using cholinesterase inhibitors |
| 04/29/2004 | WO2004034959A2 Multiparticulate modified release composition comprising beraprost |
| 04/29/2004 | WO2004034943A2 Process and reactor for the manufacture of powders of inhalable medicaments |
| 04/29/2004 | WO2004034890A2 Biological scaffolding material |
| 04/29/2004 | WO2004034876A2 Magnetically guided particles for radiative therapies |
| 04/29/2004 | WO2004028677A3 Perfluorocarbon emulsions with non-fluorinated surfactants |
| 04/29/2004 | WO2004019999A3 Agent delivery particle |
| 04/29/2004 | WO2004017940A3 Pharmaceutically active lipid based formulation of sn38 |
| 04/29/2004 | WO2004017914A3 Inhalation composition |
| 04/29/2004 | WO2004016221A3 Sulfonamides as potassium channel blockers |
| 04/29/2004 | WO2004011035B1 Bio-degradable microspheres for diagnosing gastroesophagal reflux |
| 04/29/2004 | WO2004006888A3 Stabilization of the profile of release of active substances from a formulation |
| 04/29/2004 | WO2004000265A3 Process for the preparation of robust formulations of valacyclovir hydrochloride tablets |
| 04/29/2004 | WO2003086369A3 Stealthy polymeric biodegradable nanospheres and uses thereof |
| 04/29/2004 | WO2003086267B1 Multi-phase, multi-compartment capsular system |
| 04/29/2004 | WO2003082798A8 Natural compounds and derivatives thereof for the prevention and treatment of cardiovascular, hepatic and renal diseases and for cosmetic applications |
| 04/29/2004 | WO2003055500A8 Pharmaceutical compositions for the treatment or prevention of osteoporosis |
| 04/29/2004 | WO2003029294A9 Spheroidal hdl particles with a defined phospholipid composition |
| 04/29/2004 | WO2003028667A9 Semisolid topical hormonal compositions and methods for treatment |
| 04/29/2004 | WO2003004517A3 Peyers's patch and/or m-celle targeting ligands |
| 04/29/2004 | WO2003003004A3 Method for identifying compounds the specifically deplete mast cells |
| 04/29/2004 | WO2002102391A3 Composition comprising nanoparticulate spironolactone |
| 04/29/2004 | WO2002090510A9 Regulating immine responses using dendritic cells |
| 04/29/2004 | WO2002066009A8 Modulated release particles for aerosol delivery |
| 04/29/2004 | WO2001095899A8 Pharmaceutical compositions comprising cannabidiol derivatives |
| 04/29/2004 | US20040082937 Method and device for the controlled delivery of parathyroid hormone |
| 04/29/2004 | US20040082936 Biocompatible, injectable aqueous solution for use in ultrasound energy assisted surgery |
| 04/29/2004 | US20040082907 Apparatus for dispensing powdered material |
| 04/29/2004 | US20040082788 Naphthalimide synthesis including amonafide synthesis and pharmaceutical preparations thereof |
| 04/29/2004 | US20040082777 Process for producing aqueous cellulose derivative dispersions |
| 04/29/2004 | US20040082764 Complex of antibodic and antibiotic with carrier |
| 04/29/2004 | US20040082682 Crosslinked, water insoluble polymer; medical equipment, drug delivery, tissue engineering |
| 04/29/2004 | US20040082660 Using latanoprost |
| 04/29/2004 | US20040082649 Bioavailability; prevent damage to cell membranes, cardiovascular disorders; vision defects; skin diosrders; anticholesterol agents; antitumor agents |
| 04/29/2004 | US20040082634 Using allantoin; skin disorders, antiulcer agents, antiinflammatory agents |
| 04/29/2004 | US20040082600 Bioavailability; oral administering; cardiovascular disorders; sexual disorders |
| 04/29/2004 | US20040082593 Mixing with aqueous solution containing sulfuric acid or sodium bisulfate; stabilization |
| 04/29/2004 | US20040082558 Administration of estradiol metabolites for inhibition of drug-induced nephrotoxicity |
| 04/29/2004 | US20040082545 Transferring sodium hydroxide solution to container; osteoporosis, antitumor agents |
| 04/29/2004 | US20040082542 Useful as modulators of interaction between receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, beta-amyloid and amphoterin |
| 04/29/2004 | US20040082537 Powder comprising water-containing beta-maltose crystals and production process and use thereof |
| 04/29/2004 | US20040082531 Containing a transcription regulatory sequence derived from Human Cytomegalovirus major immediate early gene that includes exon 1, but not intron A; use of such vectors in vaccine and pharmaceutical compositions and gene therapy |
| 04/29/2004 | US20040082527 Selected from the group of form D and E, F, G, J, M in the absence of azithromycin dihydrate, N, O, P, Q, and R; nuclear magnetic resonance spectrum analysis; bactericides; antiprotozoa agents; infections of mammals, birds and fish; drug resistance |
| 04/29/2004 | US20040082523 Composition for the prevention of osteoporosis comprising a combination of isoflavones and polyunsaturated fatty acids |
| 04/29/2004 | US20040082521 Uses variety of liposomal-digitalis glycoside compositions; also provides protein-stabilized nanoparticle formulations containing liposomal-digitalis glycosides such as Oleandrin, digitoxin, and digoxin with reduced toxicity |
| 04/29/2004 | US20040082520 Comprising an alkyl-polyglycoside surfactant and a medicament for inhalation |